Bepirovirsen (Hibsago) Market Size, Share, Trends & Growth Opportunities Forecast to 2026 - 2035 - Table of Contents
1. Introduction
- 1.1 Market Definition and Scope
- 1.2 Research Methodology
- 1.3 Data Sources and Assumptions
- 1.4 Abbreviations
2. Executive Summary
- 2.1 Bepirovirsen (Hibsago) Market Snapshot, 2027 and 2035
- 2.2 Key Findings
- 2.3 Analyst Recommendations
3. Disease and Product Overview
- 3.1 Chronic Hepatitis B Overview
- 3.2 Epidemiology and Patient Pool
- 3.3 Bepirovirsen Mechanism of Action
- 3.4 Dosing and Administration
- 3.5 Current Treatment Landscape
4. Clinical Evidence
- 4.1 B-Well 1 and B-Well 2 Phase III Results
- 4.2 Response by Baseline HBsAg Level
- 4.3 Safety and Tolerability
- 4.4 Ongoing and Combination Studies
5. Regulatory and Market Access
- 5.1 Approval Status by Country
- 5.2 Label and Eligibility Criteria
- 5.3 Pricing and Reimbursement Analysis
- 5.4 HBsAg Testing Landscape
6. Market Dynamics
- 6.1 Drivers
- 6.2 Restraints
- 6.3 Opportunities
- 6.4 Challenges
- 6.5 Key Trends, 2026
7. Bepirovirsen Market, By Baseline HBsAg Level, 2026–2035 (USD Million)
- 7.1 ≤100 IU/mL
- 7.2 >100 to ≤1,000 IU/mL
- 7.3 >1,000 to ≤3,000 IU/mL
8. Bepirovirsen Market, By HBeAg Status, 2026–2035 (USD Million)
- 8.1 HBeAg-Negative
- 8.2 HBeAg-Positive
9. Bepirovirsen Market, By End User, 2026–2035 (USD Million)
- 9.1 Hospital Hepatology & Gastroenterology Centers
- 9.2 Specialty Clinics
- 9.3 Community Health Centers & Others
10. Bepirovirsen Market, By Distribution Channel, 2026–2035 (USD Million)
- 10.1 Specialty Pharmacies
- 10.2 Hospital Pharmacies
- 10.3 Retail & Online Pharmacies
11. North America Bepirovirsen Market, 2026–2035 (USD Million)
- 11.1 Market by Segment
- 11.2 U.S.
- 11.3 Canada
12. Europe Bepirovirsen Market, 2026–2035 (USD Million)
- 12.1 Market by Segment
- 12.2 Germany
- 12.3 France
- 12.4 U.K.
- 12.5 Italy
- 12.6 Spain
- 12.7 Rest of Europe
13. Japan Bepirovirsen Market, 2026–2035 (USD Million)
- 13.1 Market by Segment
14. China Bepirovirsen Market, 2026–2035 (USD Million)
- 14.1 Market by Segment
15. Rest of Asia Pacific Bepirovirsen Market, 2026–2035 (USD Million)
- 15.1 Market by Segment
- 15.2 South Korea
- 15.3 Taiwan
- 15.4 Australia
- 15.5 Others
16. Latin America Bepirovirsen Market, 2026–2035 (USD Million)
- 16.1 Market by Segment
- 16.2 Brazil
- 16.3 Mexico
- 16.4 Rest of Latin America
17. Middle East & Africa Bepirovirsen Market, 2026–2035 (USD Million)
- 17.1 Market by Segment
- 17.2 GCC Countries
- 17.3 South Africa
- 17.4 Rest of Middle East & Africa
18. Competitive Landscape
- 18.1 Market Share Analysis
- 18.2 Chronic Hepatitis B Pipeline Analysis
- 18.3 Licensing and Partnerships
- 18.4 Competitive Benchmarking
19. Company Profiles (Overview, Financials, Product Portfolio, Strategy, Recent Developments)
- 19.1 GSK plc
- 19.2 Ionis Pharmaceuticals
- 19.3 Sino Biopharmaceutical (Chia Tai Tianqing)
- 19.4 Gilead Sciences
- 19.5 Aligos Therapeutics
- 19.6 Arbutus Biopharma
- 19.7 Arrowhead Pharmaceuticals
- 19.8 Vir Biotechnology
20. Appendix
- 20.1 Research Assumptions
- 20.2 Related Reports
- 20.3 About Ameco Research